Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease

Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease.

Due to several unfavorable epidemiological changes, chronic kidney disease (CKD) and treatment of its associated cardiovascular morbidity have become a worldwide problem. Thus, atrial fibrillation (AF) is the most common arrhythmia and frequently associated with renal impairment: prevalence for AF is up to 27% in long-term hemodialysis patients and in general more than 25% in all CKD patients 7...

Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.

BACKGROUND Atrial fibrillation (AF) frequently occurs in patients with chronic kidney disease (CKD). However, the long-term impact of development of AF on the risk of adverse renal outcomes in patients with CKD is unknown. In this study, we determined the association between incident AF and risk of end-stage renal disease (ESRD) among adults with CKD. METHODS AND RESULTS We studied adults wit...

Anticoagulation in Atrial Fibrillation

Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, ...

Anticoagulation in atrial fibrillation

Atrial fibrillation (AF) affects approximately 300,000 Australians and has a growing prevalence. It is associated with high rates of death and disability. The majority of people with AF are eligible to be treated with anticoagulant medications, but practice is often inadequate, leaving many people at risk of stroke. Until recently, the only antithrombotics available to prevent stroke in people ...

Oral Anticoagulation in Patients with End Stage Renal Disease and Atrial Fibrillation: The Need to Evaluate Net Clinical Effect.